SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biowa who wrote (2312)2/28/2001 12:34:54 PM
From: scaram(o)ucheRead Replies (1) of 4974
 
No, but why do we need a "test" to draw reasonable conclusions? Even in the worst of times, we had Agouron. One product approval, and it completed a ten-bagger run from 1995. Moreover, it tripled in the short span following Johnson's brave move to go to the public markets for money to make the final run.

And, as we know, Warner Lambert coughed up a wise $2.1 billion in '99.

Given a leveraged business plan and a given single success that addresses a market of decent size, appreciation will follow. If general market lethargy means that it doesn't happen instantaneously, so much the better...... back up the truck.

So...... your point is moot, even without my valid liquidity argument.

;-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News